{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447857485
| IUPAC_name = 5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
| image = Ibopamine.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|ibopamine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66195-31-1
| ATC_prefix = C01
| ATC_suffix = CA16
| ATC_supplemental =  {{ATC|S01|FB03}}
| PubChem = 68555
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8ZCA2I2L11
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04488
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 61829
|  smiles = O=C(Oc1cc(ccc1OC(=O)C(C)C)CCNC)C(C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = WDKXLLJDNUBYCY-UHFFFAOYSA-N

<!--Chemical data-->
| C=17 | H=25 | N=1 | O=4 
| molecular_weight = 307.385 g/mol
}}
'''Ibopamine''' is a [[sympathomimetic]] drug, designed as a [[prodrug]] of [[epinine]], used in [[ophthalmology]].<ref name="pmid17187138">{{cite journal |vauthors=Magacho L, Costa ML, Dessimoni A, de Avila MP |title=Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability |journal=Arq Bras Oftalmol |volume=69 |issue=5 |pages=695–9 |year=2006 |pmid=17187138 |doi= 10.1590/S0004-27492006000500015|url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492006000500015&lng=en&nrm=iso&tlng=en}}</ref> It induces [[mydriasis]].<ref name="pmid11436942">{{cite journal |vauthors=Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L |title=Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure |journal=J Ocul Pharmacol Ther |volume=17 |issue=3 |pages=215–23 |date=June 2001 |pmid=11436942 |doi=10.1089/108076801750295254}}</ref> It also has been investigated for use in the treatment of [[congestive heart failure]].<ref name="pmid7901256">{{cite journal  |vauthors=van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, etal |title=Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT) |journal=J. Am. Coll. Cardiol. |volume=22 |issue=6 |pages=1564–73 |date=November 1993 |pmid=7901256 |doi= 10.1016/0735-1097(93)90579-P|url=}}</ref>

It acts on [[Dopamine receptor D1|D<sub>1</sub>]]<ref name="pmid7630152">{{cite journal |vauthors=Metra M, Missale C, Spano PF, Cas LD |title=Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine |journal=J. Cardiovasc. Pharmacol. |volume=25 |issue=5 |pages=732–40 |date=May 1995 |pmid=7630152 |doi= 10.1097/00005344-199505000-00008|url=}}</ref><ref name="pmid7498209">{{cite journal  |vauthors=Lieverse AG, Girbes AR, Van Veldhuisen DJ, etal |title=The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure |journal=Eur. Heart J. |volume=16 |issue=7 |pages=937–42 |date=July 1995 |pmid=7498209 |doi= |url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7498209}}</ref> and  [[Adrenergic receptor#.CE.B1 receptors|α]] receptors as an [[agonist]].<ref name="urlIngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re...">{{cite web |url=http://www.ingentaconnect.com/content/ben/cdth/2007/00000002/00000002/art00006 |title=IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re... |format= |work= |accessdate=}}</ref>

Ibopamine was first prepared by Casagrande and co-workers.<ref>{{cite journal | last1 = Casagrande | first1 = C. | last2 = Santangelo | first2 = F. | last3 = Saini | first3 = C. | last4 = Doggi | first4 = F. | last5 = Gerli | first5 = F. | last6 = Cerri | first6 = O. | year = 1986 | title = Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites | url = | journal = Arzneimittelforschung | volume = 36 | issue = | pages = 291–303 }}</ref>

Instilled at 2% concentration, ibopamine exhibits several functions at ocular level such as pre- and post-operative mydriatic activity, D1 dopaminergic activity, etc.<ref>{{Cite journal|title = Ibopamine Stimulates &#945;-Adrenergic Receptors and D1 Dopaminergic Receptors in the Eye|url = http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8855&volume=2&issue=2&spage=127|journal = Current Drug Therapy|pages = 127–132|volume = 2|issue = 2|doi = 10.2174/157488507780619112|first = Italo|last = Giuffre}}</ref>

== Pharmacokinetics ==

Due to the esterases existed in the aqueous humour and ocular tissues,

ibopamine can be rapidly hydrolysed to epinine which is the active molecule responsible for the mydriatic effect.<ref>{{Cite journal|title = Ocular Pharmacokinetics and Pharmacodynamics in Rabbits of Ibopamine, a New Mydriatic Agent|url = http://www.sciencedirect.com/science/article/pii/S0014483583710328|journal = Experimental Eye Research|date = 1993-02-01|pages = 247–254|volume = 56|issue = 2|doi = 10.1006/exer.1993.1032|first = Luciano|last = Soldati|first2 = Valter|last2 = Gianesello|first3 = Isabella|last3 = Galbiati|first4 = Annibale|last4 = Gazzaniga|first5 = Michele|last5 = Virno}}</ref> The epinine, an analogue of dopamine, can stimulate dopamine receptors and to a lesser degree adrenergic receptors.<ref>{{Cite journal|title = Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.|url = http://circ.ahajournals.org/content/73/4/740|journal = Circulation|date = 1986-04-01|issn = 0009-7322|pmid = 3948372|pages = 740–748|volume = 73|issue = 4|doi = 10.1161/01.CIR.73.4.740|language = en|first = S. I.|last = Rajfer|first2 = J. D.|last2 = Rossen|first3 = F. L.|last3 = Douglas|first4 = L. I.|last4 = Goldberg|first5 = T.|last5 = Karrison}}</ref> Thus it is believed that epinine is the pharmacologically active moiety.  It has been shown that the half-life of ibopamine is short to about 2 minutes in the aqueous humour owing to the fast hydrolysis.<ref>{{Cite journal|title = Topical Ibopamine in the Treatment of Chronic Ocular Hypotony Attributable to Vitreoretinal Surgery, Uveitis, or Penetrating Trauma|url = http://linkinghub.elsevier.com/retrieve/pii/S0002939405010767|journal = American Journal of Ophthalmology|pages = 571–573|volume = 141|issue = 3|doi = 10.1016/j.ajo.2005.09.034|first = Luana Cahya|last = Ugahary|first2 = Elisabeth|last2 = Ganteris|first3 = Marc|last3 = Veckeneer|first4 = Adam C.|last4 = Cohen|first5 = Jan|last5 = Jansen|first6 = Paul G.H.|last6 = Mulder|first7 = Jan C. van|last7 = Meurs}}</ref> So ibopamine can not be found in the aqueous humor after instillation.

== Pharmacodynamics ==

After being hydrolysed to epinine, ibopamine is able to stimulate the alpha-adrenergic and D1 dopaminergic receptors, thereby exhibiting mydriatic effects.<ref>{{Cite journal|title = Ocular Pharmacokinetics and Pharmacodynamics in Rabbits of Ibopamine, a New Mydriatic Agent|url = http://www.sciencedirect.com/science/article/pii/S0014483583710328|journal = Experimental Eye Research|date = 1993-02-01|pages = 247–254|volume = 56|issue = 2|doi = 10.1006/exer.1993.1032|first = Luciano|last = Soldati|first2 = Valter|last2 = Gianesello|first3 = Isabella|last3 = Galbiati|first4 = Annibale|last4 = Gazzaniga|first5 = Michele|last5 = Virno}}</ref> In some randomized clinical trials, the D1 dopaminergic activity of ibopamine led to an increased production of aqueous humour and intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients.<ref>{{Cite journal|title = Ibopamine in glaucoma diagnostics: a new pharmacological provocative test|url = https://link.springer.com/article/10.1007/BF00212962|journal = International Ophthalmology|date = 1996-01-01|issn = 0165-5701|pages = 151–155|volume = 20|issue = 1-3|doi = 10.1007/BF00212962|language = en|first = Fabio De|last = Gregorio|first2 = Josè Pecori|last2 = Giraldi|first3 = Luigi|last3 = Pannarale|first4 = Silvia|last4 = Saccucci|first5 = Michele|last5 = Virno}}</ref>

== Toxicology ==

At systemic and local levels, ibopamine has been proved to be of low toxicity. It is well-tolerated since no obvious changes to the haematological and behavioural parameters have been observed after administration.<ref>{{Cite book|title = Ibopamine – A New Alpha-Adrenergic and D1-Dopaminergic Drug|url = http://www.intechopen.com/books/ophthalmology-current-clinical-and-research-updates/ibopamine-a-new-alpha-adrenergic-and-d1-dopaminergic-drug|publisher = InTech|date = 2014-09-03|doi = 10.5772/58380|language = en|first = Italo|last = Giuffre}}</ref> Ibopamine eye drop at 2% concentration, containing 1&nbsp;mg of the compound, did not show any significant systemic side-effects and tachyphylaxis phenomena whereas the oral dosage is higher than 400&nbsp;mg per day.<ref>{{Cite journal|title = Ibopamine Stimulates α-Adrenergic Receptors and D1 Dopaminergic Receptors in the Eye|url = http://www.ingentaconnect.com/content/ben/cdth/2007/00000002/00000002/art00006|journal = Current Drug Therapy|date = 2007-05-01|pages = 127–132|volume = 2|issue = 2|doi = 10.2174/157488507780619112|first = Italo|last = Giuffre}}</ref>

== Clinical Use ==

A fast and short-lasting mydriasis can be induced by ibopamine without systemic side-effects.

==See also==
* [[Epinine]]

== References ==

{{reflist|2}}

{{Cardiac stimulants excluding cardiac glycosides}}
{{Mydriatics and cycloplegics}}

[[Category:Alpha-adrenergic agonists]]
[[Category:D1-receptor agonists]]
[[Category:Phenethylamines]]
[[Category:Isobutyrates]]